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The G protein-coupled histamine H4 receptor (H4R) is the 
last member of histamine receptors family discovered 
so far. Its expression pattern, together with postulated 
involvement in a wide variety of immunological and in-
flammatory processes make histamine H4 receptor an 
interesting target for drug development. Potential H4R 
ligands may provide an innovative therapies for differ-
ent immuno-based diseases, including allergy, asthma, 
pruritus associated with allergy or autoimmune skin con-
ditions, rheumatoid arthritis and pain. However, none of 
successfully developed selective and potent histamine H4 
receptor ligands have been introduced to the market up 
to date. For that reason there is still a strong demand for 
pharmacological models to be used in studies on potent 
H4R ligands. In current work we present the develop-
ment of novel mammalian cell line, stably expressing hu-
man histamine H4 receptor, with use of retroviral trans-
duction approach. Obtained cell line was pharmacologi-
cally characterized in radioligand binding studies and its 
utility for affinity testing of potent receptor ligands was 
confirmed in comparative studies with the use of rel-
evant insect cells expression model. Obtained results al-
low for statement that developed cellular model may be 
successfully employed in search for new compounds ac-
tive at histamine H4 receptor.
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INTRODUCTION
Human histamine H4 receptor, being a biological tar-
get of presented studies is, by far, the last histamine re-
ceptor discovered. Its gene has been cloned ca. 2000, 
independently by several groups (Leurs et al., 2009). 
Histamine H4 receptor expression on basophils, eosino-
phils, mast cells and dendritic T cells suggests its role 
in immunological answer (Nguyen et al., 2001). Therefore 
its ligands could provide promising drugs for immuno-
based diseases (Jablonowski et al., 2004; Tiligada et al., 
2009; Zampeli & Tiligada, 2009), however none of the 
potent ligands was brought to the market so far. Thus, 
histamine H4 receptor remains an important target in 
drug development (Smits et al., 2009) and for that reason 
development of new experimental models for pharmaco-
logical studies of receptor ligands is still a scientific issue 
of high importance.
Recombinant receptors systems are pharmacologi-
cal tools widely utilized in search for novel ligands of 
G-protein coupled receptors (GPCRs) (Kenakin, 1996). 
Contrary to historically used native receptors systems, 
they can be involved in studies on poorly characterized 
receptors, for which selective ligands are not known and 
low expression levels are observed in native cells (Sar-
ramegna et al., 2003). On the other hand, main limita-
tions of recombinant receptors experiments include: the 
risk of measuring artifacts, related to disrupted propor-
tions of receptors and G proteins molecules (Kenakin, 
1997) as well as influence of artificial  environment of 
host cells devoid of natural allosteric modulators (e.g. 
other receptors) (Haack & McCarty, 2011) or functional 
specialization. Despite mentioned disadvantages heterol-
ogous expression of GPCRs is dominantly used for de-
velopment of models for molecular pharmacology stud-
ies on metabotropic receptors.
Recombinant proteins can be obtained in various ex-
pression systems (Baldi et al., 2007). In studies on GP-
CRs, mammalian cell lines are predominantly used. 
These models guarantee satisfactory grade of posttrans-
lational protein modifications and enable cellular mem-
brane localization of recombinant proteins. Moreover, 
mammalian cells contain whole range of necessary intra-
cellular signaling pathway elements (Hermans, 2004; Sie-
hler, 2008). In the group of cells most frequently used 
in recombinant receptors production — CHO (Chinese 
hamster ovary) cell line is playing a dominant role, due 
to easiness of cell culture and transfection, lack of signif-
icant expression of many investigated receptor in wild-
type cells and confirmed in numerous experiments use-
fulness of mentioned cell line for studies on G-protein 
coupled receptors pharmacology (Gazi et al., 1999; Nash 
et al., 2001). 
Gene transfer to the considered cells in recombinant 
protein production procedure can be achieved by means 
of transfection or viral transduction. Retroviral trans-
duction system is an example of second method. It is 
based on the coordinated design of packaging cell lines 
and retroviral expression vectors (Morgenstern & Land, 
1990; Cepko & Pear, 2001). To develop a packaging cell 
line, the viral gag, pol and env genes are stably integrated 
into the genome of the packaging cell line (Markovitz et 
al., 1988). The separate introduction and integration of 
the structural genes minimizes the chances of producing 
replication-competent virus due to recombination events 
during cell proliferation. Retroviral expression vectors 
provide the packaging signal Psi+, transcription and pro-
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cessing elements and a target gene. Once a packaging 
cell line is transfected with a retroviral expression vector 
that contains a packaging signal, the viral genomic tran-
script containing the target gene and a selectable mark-
er are packaged into infectious viruses within 48–72 h. 
Produced virus can infect target cells and transmit target 
genes; however, it cannot replicate within target cells be-
cause the viral structural genes are absent.
Described technique was used in current study to ex-
press human histamine H4 receptor in CHO cells. As the 
obtained cell line is supposed to be used in affinity test-
ing of potent receptor ligands it was basically character-
ized in various radioligand binding assays.
MATERIALS AND METHODS
Reagents. The pcDNA 3.1 plasmid, contain-
ing human histamine H4 receptor cDNA sequence 
(pcDNA3.1-hH4R), consistent with GenBank database 
entry No. AY136745 (Benson et al., 2013) was obtained 
from Missouri S&T cDNA Resource Center, Rolla, 
MO, U.S. Packaging cell line GP+envAM12 (Markovitz 
et al., 1988) was a kind gift from Prof. Dr. C.E. Müller 
(Pharma-Zentrum, Bonn, Germany). Baculoviruses en-
coding the human histamine H4 receptor were prepared 
as described recently (Schneider et al., 2009). Baculovi-
ruses encoding the G proteins Gαi2 and Gβ1γ2 subunits 
together with Sf9 cells were kindly provided by Prof. Dr. 
Holger Stark (Institute for Pharmaceutical and Medici-
nal Chemistry, Heinrich-Heine-University Duesseldorf, 
Germany). 4-methylpiperazino-amide derivatives (H4-21, 
H4-23, DB-5-DB-7) were synthesized in the Depart-
ment of Technology and Biotechnology of Drugs, Medi-
cal College, Jagiellonian University, Kraków as described 
previously (Karcz et al., 2010). Unlabelled histamine was 
from Sigma-Aldrich, St. Luis, MO, U.S. Radioactively 
labelled [3H]histamine (specific activity 10.6 Ci/mmol) 
and reference membrane preparations from CHO cells 
stably expressing hH4R were obtained from PerkinElm-
er, Waltham, MA, U.S. Stock solutions (10 mM) of test 
compounds were prepared in DMSO. 
Molecular cloning. Human histamine H4 recep-
tor cDNA was obtained by PCR amplification from 
pcDNA3.1-hH4R plasmid using forward primer intro-
ducing BamHI recognition sequence and reverse primer 
carrying NotI restriction site. The entire cDNA sequence 
was then introduced into pQCXIN retroviral vector (Ta-
kara Bio Europe/Clontech Inc., Saint-Germain-en-Laye, 
France) with BamHI/NotI restriction enzymes, creating 
pQCXIN-hH4R vector. The result of molecular cloning 
experiment was confirmed by means of restriction analy-
sis and DNA sequencing.
Retroviral transduction system. The packing cell 
line (GP+envAM12) was splitted one day before trans-
fection (1.0×106 in 25 cm2 flask) in DMEM medium, 
supplemented with 10%  (v/v) fetal bovine serum. Cells 
were transfected by using TurboFect reagent (Thermo 
Fisher Scientific Inc., Waltham, MA, U.S.). Briefly, 18 μg 
of DNA (11.25 μg of pQCXIN-hH4R plasmid and 6.75 
μg of pcDNA3.1-VSV-G — encoding G Protein of Ve-
sicular Stomatitis Virus) was diluted to final volume of 
600 μl with DMEM (without FBS or antibiotics); then, 
24 μl of TurboFect reagent was added to the diluted 
DNA and obtained mixture was incubated for 15 min-
utes before adding to the GP+envAM12 cells (80% con-
fluent; 25 cm2 flask). 14 hours after transfection of pack-
aging cells culture medium was changed with 3 ml of 
fresh medium (DMEM, 10% (v/v) FBS, 100 U/ml peni-
cillin G, 100 μg/ml) and 30 μl of sodium butyrate (500 
mM in H2O) was added. The cells were further cultured 
at 32°C for 48 h. Finally, 3 ml of virus supernatant were 
collected and filtered through 45 μm filter. The sterile 
virus supernatant together with 2.4 μl of polybrene solu-
tion (10 mg/ml in H2O) was transferred into CHO cells 
culture (80% confluent, 25 cm2 flask) for 2 hours and af-
ter that time medium was exchanged for a new one. 48 
hours post-transduction cells were subcultured in growth 
medium containing 800 μg/ml geneticin and the selec-
tion of the positive clones was continued for two weeks. 
Resultant cell line: CHO-hH4R, expressing human hista-
mine H4 receptor was used in further experiments.
Cell culture and membranes preparation of CHO-
hH4R cells. The cells were grown in Dulbecco’s Modi-
fied Eagle Medium/Nutrient Mixture F-12 supplemented 
with 10% (v/v) fetal bovine serum, and 200 μg/ml ge-
neticin in an atmosphere of 5% CO2 at 37°C. Cells were 
grown until reaching 80–90% confluence. After medium 
removal cells were washed with sterile PBS buffer and 
frozen at –80°C until further preparation. 
Thawed cells were collected in 5 mM Tris/HCl and 2 
mM EDTA, pH 7.4 (Tris/EDTA buffer) and were ho-
mogenized using Ultra-Turrax homogenizer. The result-
ing suspension was centrifuged at 1000 × g for 10 min to 
remove unbroken cells and nuclei. The supernatant was 
homogenized again with Ultra-Turrax and subsequently 
centrifuged at 48 000 × g for 60 min. The resulting pellets 
ware resuspended in 50 mM Tris/HCl buffer, pH 7.4. 
Determination of membrane protein concentration was 
carried out by the method of Lowry and obtained mem-
branes were stored at –80°C until required.
Cell culture and membrane preparation of Sf9 
cells expressing the human histamine H4 receptor. 
Sf9 cells were cultured in 250 ml Spinner flasks at 28°C 
under rotation at 100 rpm in SF 900 II medium sup-
plemented with 5% (v/v) fetal bovine serum and peni-
cillin (50 U/ml)/streptomycin (50 μg/ml) under normal 
atmosphere. Cells were grown at a density of 3×106 
cells/ml and were infected with a combination of bac-
ulovirus stock solutions (1:100), each encoding for the 
human histamine H4 receptor and G protein Gαi2 and 
Gβ1γ2 subunits. 48 h after infection cells were harvested. 
Sf9 membranes were prepared as described previously 
(Schneider et al., 2009) and were stored in binding buffer 
(12.5 mM MgCl2, 1 mM EDTA and 75mM Tris/HCl, 
pH 7.4) at –80°C till needed.
Radioligand binding assays at membranes prepa-
rations from recombinant CHO cells. Binding experi-
ments were carried out as follows: membranes (15 μg 
protein per well for reference preparation from commer-
cial source and 100 μg protein per well for preparation 
from retrovirally transduced CHO cells) were incubated 
with 10 nM [3H]histamine solution and different concen-
trations of the respective test ligand, spanning a range 
of at least three log units, in total volume of 0.35 ml 
of assay buffer (50 mM TRIS/HCl, 5mM EDTA, pH 
7.4). Differently, in case of saturation binding experi-
ments CHO-hH4R cells membranes were incubated with 
11 different concentrations of radioligand ranging from 
0.5 to 350 nM. In all experiment incubations were per-
formed for 60 min at 25°C with shaking and shaking at 
250 rpm and non-specific binding was determined in the 
presence of 100 µM unlabelled histamine. Bound radio-
ligand was separated from free radioligand by filtration 
through GF/B filters pretreated with 0.3% (m/v) pol-
yethyleneimine and washed eight times with 0.2 ml of 
ice-cold washing buffer (50 mM Tris/HCl, pH 7.4). The 
amount of radioactivity collected on the filter was de-
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termined by liquid scintillation counting. Determination 
of affinity values (Ki) was carried out using GraphPad 
Prism program (GraphPad Software Inc., La Jolla, CA, 
U.S.) according to Cheng-Prusoff equation (Cheng & 
Prushoff, 1973).
Radioligand binding assays at membranes prepa-
rations from recombinant Sf9 cells. Experiments were 
performed similarly to binding assays with use of CHO 
cells-based membranes preparations, however some mi-
nor modifications of protocol were included as follows. 
Assays were carried out in total volume of 0.2 ml of 
Sf9 binding buffer, containing 12.5 mM MgCl2, 1 mM 
EDTA and 75 mM Tris/HCl, pH 7.4. 35 μg of protein 
was used per single sample and GF/B filters washing 
step included three repeats with 0.5 ml of Sf9 binding 
buffer. KD constant for [3H]histamine, determined in for-
mer experiments (Kottke et al., 2011) and used for calcu-
lations of affinity values (Ki) was 11.66 nM. 
RESULTS AND DISCUSSION
The aim of the study was to develop a novel cellular 
model suitable for affinity studies of histamine H4 recep-
tor ligands. Retroviral transduction system was employed 
in order to obtain stable expression of recombinant hu-
man histamine H4 receptor protein in CHO cell line. 
Major advantage of proposed technique is achievement 
of stable and efficient integration of few copies of vi-
ral genes into a host chromosome, which is not always 
available in case of transfection methods (Cepko & Pear, 
1996).
Following the molecular biology experiments, which 
led to obtaining of pQCXIN-hH4R retroviral vector, 
containing human histamine H4 receptor cDNA se-
quence, transduction of target CHO cell line was per-
formed with use of retroviral particles produced in 
GPenv+AM12 packaging cells. Transduced cells were 
subject to selection procedure with use of selective anti-
biotic geneticin in order to isolate positive clones stably 
co-expressing receptor gene together with antibiotic re-
sistance gene from bicistronic transcript. 
Resultant cell line was tested for its utility in radio-
ligand binding assays. First, recombinant receptor was 
characterized in saturation binding assay with use of [3H]
histamine as a radioligand. Obtained results confirmed 
receptor expression in developed cell line. We were able 
to observe specific and saturable binding of radioligand 
in case of membranes preparations from developed cell 
line (Fig. 1). Basing on saturation binding experiment 
results KD constant value was determined for proposed 
assay conditions, which was later used for calculations 
of affinity values (Ki) from IC50 values in competition 
studies. [3H]histamine KD value determined in saturation 
binding experiment equaled 16.1 nM and was in accord-
ance to literature data (Jablonowski et al., 2004; Kottke et 
al., 2011).
Homological histamine competition binding assay was 
employed for comparison of obtained cell line’s proper-
ties with reference membranes preparation from com-
mercial source (PerkinElmer, Waltham, MA, U.S). Com-
parative binding experiments were performed simulta-
neously for both sources of cell membranes. Obtained 
results confirmed expected pharmacological properties 
of developed experimental model (Fig. 2). Determined 
IC50 values were in the same range for both membranes 
preparations, however expression level was significant-
ly lower in case of prepared cell line, because higher 
amount of protein had to be used in order to obtain lev-
el of specific binding  similar to commercial membranes 
(100 μg per sample vs. 15 μg per sample). Yet, usage of 
increased protein amount in assay resulted in elevated 
level of nonspecific binding (compare lower plateaus of 
curves on Fig. 2). Moderate receptor expression level in 
developed cell line may be due to erroneous folding or 
improper trafficking of recombinant protein to cellular 
membrane and its retention in subcellular compartments.
In order to finally confirm novel cell line usefulness 
for affinity studies and validate proposed assay plat-
form, competition binding experiments for estimation 
of unknown Ki values of tested compounds were per-
formed. Developed assay was validated against the insect 
cell line-related system, used for the same purposes by 
our scientific collaborators. Series of potent histamine 
Figure 1. Saturation of [3H]histamine binding to histamine H4 re-
ceptors at CHO-hH4R cells. 
Saturation binding experiment was performed in triplicates with 
use of membranes preparations from CHO cells transduced with 
retroviral particles bearing cDNA sequence of human histamine 
H4 receptor. Specific binding was determined as a difference be-
tween total binding measured in absence of unlabelled receptor 
ligand at particular [3H]histamine concentrations and nonspecific 
binding measured for respective radioligand dilutions in presence 
of histamine (100 μM).
Figure 2. Homologous competition binding of [3H]histamine to 
various membranes preparations from cells stably expressing 
histamine H4 receptor.
Homologous competition binding experiments were performed 
with use of membranes preparation from: novel cell line obtained 
with use of retroviral transduction system () and reference 
membrane preparation from commercial source (). Respective 
IC50 values determined in homologous competition binding assay 
were as follows: retroviral transduction system — IC50 = 80.2 ± 19.6 
[nM] and commercial membranes preparation — IC50 = 62.2 ± 21.9 
[nM]. Data points represent means ± S.E.M. of two independent 
experiments, performed in triplicates.
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receptor ligands were tested in competition binding as-
says vs. [3H]histamine. Considered structures represented 
4-methylpiperazino-amide derivatives and histamine was 
included as reference. Determined affinities were in a 
micromoloar range (Table 1). Histamine Ki value was in 
accordance with literature data (Leurs et al., 2009). Esti-
mated affinities correlated well with the results obtained 
in formerly used insect cells model for all investigated 
compounds (Fig. 3). The most active compound in pre-
sent series was (3-chlorophenyl)carbonyl-4-methylpip-
erazine (H4-23),  showing respective Ki values of  3.12 
μM for CHO cells stably expressing human histamine 
H4 receptor, obtained with use of retroviral transduction 
system and 3.88 μM for insect cells infected with bacu-
lovirus encoding for the human histamine H4 receptor 
(Fig. 4). 
To conclude, we obtained a novel mammalian cell 
line expressing functional human histamine H4 receptor 
with use of retroviral transduction system, which was 
confirmed in a variety of radioligand studies. Developed 
cellular model is suitable for investigation of potent his-
tamine H4 receptor ligands affinities.
Table 1. Comparison of Ki values of potent histamine H4 receptor ligands, estimated in affinity assay with use of different receptor 
expression models. 
Competition binding experiments were performed at membranes preparations from: CHO cells stably expressing human histamine H4 
receptor, obtained with the use of retroviral transduction system (RTS) and insect cells infected with baculovirus encoding for the human 
histamine H4 receptor (Sf9).
Figure 3. Correlation between pKi values obtained for consid-
ered histamine H4 receptor ligands in two compared receptor 
expression systems. 
pKi values determined for tested compounds (histamine, H4-21, 
H4-23, DB-5, DB-6 and DB-7) with use of membranes prepara-
tions from recombinant cell line obtained with the use of retrovi-
ral transduction system (RTS) were compared with relevant results 
developed basing on membranes from genetically modified Spo-
doptera frugiperda cells (Sf9).
Figure 4. Competition binding curve for compound H4-23 vs. 
[3H]histamine, obtained at membranes preparation of retrovi-
rally transduced CHO cells stably expressing human histamine 
H4 receptor. 
Presented competition binding experiment was performed for 
H4-23, a most potent hH4R ligand of investigated series of 4-meth-
ylpiperazino-amide derivatives. Determined IC50 parameter was 
used, according to Cheng-Prusoff equation, to calculate Ki value 
(3.12 ± 0.80 μM). Data points represent means ± S.E.M. of two in-
dependent experiments, performed in duplicates.
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